140 related articles for article (PubMed ID: 10589745)
1. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.
Yuen AR; Halsey J; Fisher GA; Holmlund JT; Geary RS; Kwoh TJ; Dorr A; Sikic BI
Clin Cancer Res; 1999 Nov; 5(11):3357-63. PubMed ID: 10589745
[TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.
Nemunaitis J; Holmlund JT; Kraynak M; Richards D; Bruce J; Ognoskie N; Kwoh TJ; Geary R; Dorr A; Von Hoff D; Eckhardt SG
J Clin Oncol; 1999 Nov; 17(11):3586-95. PubMed ID: 10550158
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
Tolcher AW; Reyno L; Venner PM; Ernst SD; Moore M; Geary RS; Chi K; Hall S; Walsh W; Dorr A; Eisenhauer E
Clin Cancer Res; 2002 Aug; 8(8):2530-5. PubMed ID: 12171880
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
Cunningham CC; Holmlund JT; Schiller JH; Geary RS; Kwoh TJ; Dorr A; Nemunaitis J
Clin Cancer Res; 2000 May; 6(5):1626-31. PubMed ID: 10815879
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
Stevenson JP; Yao KS; Gallagher M; Friedland D; Mitchell EP; Cassella A; Monia B; Kwoh TJ; Yu R; Holmlund J; Dorr FA; O'Dwyer PJ
J Clin Oncol; 1999 Jul; 17(7):2227-36. PubMed ID: 10561280
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice.
Geiger T; Müller M; Dean NM; Fabbro D
Anticancer Drug Des; 1998 Jan; 13(1):35-45. PubMed ID: 9474241
[TBL] [Abstract][Full Text] [Related]
9. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
Cripps MC; Figueredo AT; Oza AM; Taylor MJ; Fields AL; Holmlund JT; McIntosh LW; Geary RS; Eisenhauer EA
Clin Cancer Res; 2002 Jul; 8(7):2188-92. PubMed ID: 12114419
[TBL] [Abstract][Full Text] [Related]
10. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.
Advani R; Peethambaram P; Lum BL; Fisher GA; Hartmann L; Long HJ; Halsey J; Holmlund JT; Dorr A; Sikic BI
Cancer; 2004 Jan; 100(2):321-6. PubMed ID: 14716767
[TBL] [Abstract][Full Text] [Related]
11. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
[TBL] [Abstract][Full Text] [Related]
12. Technology evaluation: ISIS-3521.
Li K; Zhang J; Sirois P; Hu Y
Curr Opin Mol Ther; 1999 Jun; 1(3):393-8. PubMed ID: 11713804
[TBL] [Abstract][Full Text] [Related]
13. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.
Benimetskaya L; Miller P; Benimetsky S; Maciaszek A; Guga P; Beaucage SL; Wilk A; Grajkowski A; Halperin AL; Stein CA
Mol Pharmacol; 2001 Dec; 60(6):1296-307. PubMed ID: 11723237
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer.
Marshall JL; Eisenberg SG; Johnson MD; Hanfelt J; Dorr FA; El-Ashry D; Oberst M; Fuxman Y; Holmlund J; Malik S
Clin Colorectal Cancer; 2004 Nov; 4(4):268-74. PubMed ID: 15555210
[TBL] [Abstract][Full Text] [Related]
16. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
O'Dwyer PJ; Stevenson JP; Gallagher M; Cassella A; Vasilevskaya I; Monia BP; Holmlund J; Dorr FA; Yao KS
Clin Cancer Res; 1999 Dec; 5(12):3977-82. PubMed ID: 10632328
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.
Advani R; Lum BL; Fisher GA; Halsey J; Geary RS; Holmlund JT; Kwoh TJ; Dorr FA; Sikic BI
Invest New Drugs; 2005 Oct; 23(5):467-77. PubMed ID: 16133798
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
Plummer R; Vidal L; Griffin M; Lesley M; de Bono J; Coulthard S; Sludden J; Siu LL; Chen EX; Oza AM; Reid GK; McLeod AR; Besterman JM; Lee C; Judson I; Calvert H; Boddy AV
Clin Cancer Res; 2009 May; 15(9):3177-83. PubMed ID: 19383817
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.
Maksymowych WP; Blackburn WD; Tami JA; Shanahan WR
J Rheumatol; 2002 Mar; 29(3):447-53. PubMed ID: 11908555
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys.
Monteith DK; Geary RS; Leeds JM; Johnston J; Monia BP; Levin AA
Toxicol Sci; 1998 Dec; 46(2):365-75. PubMed ID: 10048140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
